BeOne MedicinesMEX:BGNEN 81 Gross Margin % is 88.95% as of Mar. 2026, which is 5% above its 10-year median of 84.55. GuruFocus rates MEX:BGNEN with a GF Score™ of 81/100 and a GF Value™ of MXN3,774.03. The stock has 4 warning signs investors should review. Among 738 Biotechnology companies, BeOne Medicines ranks better than 81.57% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
BeOne Medicines had a gross margin of 88.95% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
BeOne Medicines Gross Margin % Related Terms
BeOne Medicines Gross Margin % Historical Data
* Premium members only.
The historical data trend for BeOne Medicines's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:BGNEN vs RVMD, RPRX, BNTX: Gross Margin % Comparison
For the Biotechnology subindustry, BeOne Medicines's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BeOne Medicines Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BeOne Medicines's Gross Margin % distribution charts can be found below:
* The bar in red indicates where BeOne Medicines's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
BeOne Medicines (MEX:BGNEN) has a Gross Margin % of 88.95% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on BeOne Medicines and its competitors. This is near median its historical median of 84.55. Over the past decade, BeOne Medicines' Gross Margin % has ranged from 77.12 to 97.91. According to the industry distribution chart, BeOne Medicines ranks #136 out of 738 companies in the Biotechnology industry, placing it in the top 18.4%.
Is BeOne Medicines' Gross Margin % too high?
BeOne Medicines' current Gross Margin % of 88.95% is near median its 10-year median of 84.55. Over the past 10 years, this metric has ranged from a low of 77.12 to a high of 97.91. The Biotechnology industry median Gross Margin % is 60.94. BeOne Medicines' value of 88.95% is 46% above this industry median. Based on the distribution chart, BeOne Medicines ranks #136 out of 738 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BeOne Medicines has a GF Score™ of 81/100, reflecting its overall financial health beyond just this single metric.
How does BeOne Medicines' Gross Margin % compare to RVMD and RPRX?
According to the Biotechnology industry distribution chart, BeOne Medicines ranks #136 out of 738 companies for Gross Margin %. This places BeOne Medicines in the top 18% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.94. BeOne Medicines' value of 88.95% is 46% above this benchmark. Historically, BeOne Medicines' own Gross Margin % has ranged from 77.12 to 97.91 over the past decade. While the company's 10-year median is 84.55 vs. the industry median of 60.94, BeOne Medicines has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.94, based on 738 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BeOne Medicines's current Gross Margin % of 88.95% is 46% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on BeOne Medicines and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BeOne Medicines's current Gross Margin % is 88.95%, which is near median its own 10-year median of 84.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeOne Medicines stock overvalued right now?
BeOne Medicines (MEX:BGNEN) has a current Gross Margin % of 88.95%. The stock's GF Value™ is MXN3,774.03, compared to a current price of MXN2,858.16 — trading 24.3% below its estimated fair value. The current Gross Margin % is 88.95%, which is near median its 10-year median of 84.55 and 46% above the Biotechnology industry median of 60.94. BeOne Medicines' overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For BeOne Medicines (MEX:BGNEN), the current Gross Margin % is 88.95% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BeOne Medicines (MEX:BGNEN) Overvalued in 2026?
Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued.
The current stock price of MXN2,858.16 is trading 24.3% below its estimated GF Value™ of MXN3,774.03.
Key valuation signals for MEX:BGNEN:
Gross Margin %: 88.95% (near median its 10-year median of 84.55)
GF Value™: MXN3,774.03 vs. price of MXN2,858.16 (24.3% below fair value)
Industry Position: 46% above the Biotechnology median (#136 of 738)
No single metric tells the full story. See the MEX:BGNEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
81GF Score
Get the complete analysis for MEX:BGNEN
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:BGNEN has been successfully added to your 
